Ac	acetyl group
ADC(s)	antibody–drug conjugate(s)
AE	adverse event
AITL	angioimmunoblastic T-cell lymphoma
ALCL	anaplastic large cell lymphoma
ALK−ALCL	anaplastic lymphoma kinase-negative anaplastic large cell lymphoma
Allo-HSCT	allogeneic hematopoietic stem cell transplantation
Auto-HSCT	autologous hematopoietic stem cell transplantation
Axi-cel	axicabtagene ciloleucel
BCR	B-cell receptor
Bel-CHOP	belinostat plus cyclophosphamide, doxorubicin, vincristine, prednisone
BR	bendamustine plus rituximab
BTK	Bruton tyrosine kinase
BTKi	Bruton tyrosine kinase inhibitor
BV	brentuximab vedotin
CAR-T	chimeric antigen receptor T-cell
Ca2+	calcium ions
CBC	complete blood count
CD	cluster of differentiation
CHOP	cyclophosphamide, doxorubicin, vincristine, prednisone
CHP	cyclophosphamide, doxorubicin, prednisone
COO	cell of origin
CR(s)	complete response(s)
CRS	cytokine release syndrome
cBTKi	covalent Bruton tyrosine kinase inhibitor
CTCL	cutaneous T-cell lymphoma
DAG	diacylglycerol
DLBCL	diffuse large B-cell lymphoma
DoR	duration of response
ECOG	Eastern Cooperative Oncology Group performance status
FL	follicular lymphoma
GVHD	graft-versus-host disease
HAT	histone acetyltransferase
HBV	hepatitis B virus
HDAC(s)	histone deacetylase(s)
HGBCL	high-grade B-cell lymphoma
HR	hazard ratio
ICANS	immune effector cell-associated neurotoxicity syndrome
Igα (CD79A)	immunoglobulin alpha chain
Igβ (CD79B)	immunoglobulin beta chain
IPI	International Prognostic Index
IP3	inositol 1,4,5-trisphosphate
IRC	independent review committee
ISRT	involved-site radiotherapy
LBCL	large B-cell lymphoma
Liso-cel	lisocabtagene maraleucel
LYN	LYN proto-oncogene, Src family tyrosine kinase
MCL	mantle cell lymphoma
MF	mycosis fungoides
MMAE	monomethyl auristatin E
MYC	MYC proto-oncogene
NCCN	National Comprehensive Cancer Network